BRPI0412459A - composto tendo ação anti-hcv e seu método de produção - Google Patents

composto tendo ação anti-hcv e seu método de produção

Info

Publication number
BRPI0412459A
BRPI0412459A BRPI0412459-6A BRPI0412459A BRPI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A
Authority
BR
Brazil
Prior art keywords
compound
hcv
production
production method
bond
Prior art date
Application number
BRPI0412459-6A
Other languages
English (en)
Inventor
Masayuki Sudoh
Takuo Tsukuda
Miyako Masubuchi
Kenichi Kawasaki
Takeshi Murata
Fumio Watanabe
Hiroshi Fukuda
Susumu Komiyama
Tadakatsu Hayase
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0412459A publication Critical patent/BRPI0412459A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

"COMPOSTO TENDO AçãO ANTI-HCV E SEU MéTODO DE PRODUçãO". O objetivo da presente invenção é fornecer um composto útil para a prevenção e tratamento de doenças infecciosas virais, e particularmente doenças do fígado causadas pela infecção por HCV, devido a isto tendo um grau elevado de atividade inibidora da replicação contra o HCV, seu método de produção, um composto intermediário útil para a sua produção e uma composição farmacêutica contendo estes compostos, e a presente invenção diz respeito a um composto representado pela fórmula (I) (em que A representa -(CH~ 2~)~ n~-, etc.; B representa -(C=O)-, etc.; D representa (CH~ 2~)~ m~-R<39>, etc.; E representa um átomo de hidrogênio, etc.; G representa (CH~ 2~)~ p~-J, etc.; a ligação Q representa uma ligação única ou ligação dupla; e R~ 1~, R~ 2~ e R~ 3~ podem ser os mesmos ou diferentes e cada um representa um átomo de hidrogênio, etc.), um pró-medicamento deste ou um sal farmaceuticamente aceitável deste.
BRPI0412459-6A 2003-07-09 2004-07-09 composto tendo ação anti-hcv e seu método de produção BRPI0412459A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003272420 2003-07-09
PCT/JP2004/009803 WO2005005372A1 (ja) 2003-07-09 2004-07-09 抗hcv作用を有する化合物およびその製法

Publications (1)

Publication Number Publication Date
BRPI0412459A true BRPI0412459A (pt) 2006-10-17

Family

ID=34055974

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412459-6A BRPI0412459A (pt) 2003-07-09 2004-07-09 composto tendo ação anti-hcv e seu método de produção

Country Status (17)

Country Link
US (1) US7378446B2 (pt)
EP (1) EP1661882B1 (pt)
JP (1) JP4068639B2 (pt)
KR (1) KR20060029182A (pt)
CN (1) CN1819990B (pt)
AU (1) AU2004255633B2 (pt)
BR (1) BRPI0412459A (pt)
CA (1) CA2531790A1 (pt)
IL (1) IL172666A0 (pt)
MX (1) MXPA06000294A (pt)
MY (1) MY143775A (pt)
NO (1) NO20055986L (pt)
NZ (1) NZ545102A (pt)
RU (1) RU2346933C2 (pt)
TW (1) TWI330173B (pt)
UA (1) UA92134C2 (pt)
WO (1) WO2005005372A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4849622B2 (ja) * 2004-08-11 2012-01-11 中外製薬株式会社 Hcv感染症を治療または予防するための薬剤
JP2006077004A (ja) * 2004-08-11 2006-03-23 Chugai Pharmaceut Co Ltd 抗hcv作用を有する化合物およびそれを含む医薬組成物
US7897783B2 (en) 2005-02-17 2011-03-01 Chugai Seiyaku Kabushiki Kaisha Intermediate compound for synthesis of viridiofungin a derivative
EP1908846A4 (en) * 2005-06-28 2011-10-26 Chugai Pharmaceutical Co Ltd METHOD FOR PRODUCING A COMPOUND WITH ANTI-HCV EFFECT
CN101360736A (zh) * 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-丙氨酸衍生物
EP2042188A4 (en) 2006-05-16 2011-11-16 Tokyo Metropolitan Org Med Res PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF HCV INFECTION
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物
WO2008093065A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
TW201010692A (en) * 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
EP2368989A4 (en) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd OLIGORIBONUCLEOTID- BZW. PEPTID NUCLEIC ACID TO INHIBIT THE ACTIVITY OF HEPATITIS C VIRUS
JP2013121935A (ja) 2011-12-12 2013-06-20 Institute Of Microbial Chemistry 化合物、及び不斉合成反応
EP2886530A4 (en) 2012-08-17 2016-01-27 Chugai Pharmaceutical Co Ltd ORAL ADMINISTRATIVE VIRIDIDEIN DERIVATIVE WITH ANTI-HCV ACTIVITY
JP7565930B2 (ja) * 2019-08-23 2024-10-11 パナソニックホールディングス株式会社 支援装置、分析装置、支援方法、分析方法、およびプログラム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364948A (en) * 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
EP0526936A3 (en) * 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
DE4415312A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Verfahren zur Herstellung von N-Acylglycinderivaten
ES2209140T3 (es) 1997-06-09 2004-06-16 Takara Bio Inc. Sustancias tkr2449 fisiologicamente activas, procedimientos para producir las mismas y microorganismo.
JP5025051B2 (ja) 2001-07-26 2012-09-12 サトーホールディングス株式会社 印字編集処理装置
JP4093534B2 (ja) 2002-03-15 2008-06-04 スタンレー電気株式会社 車両用前照灯
MY141506A (en) 2003-02-12 2010-05-14 Chugai Pharmaceutical Co Ltd Virus therapeutic drug

Also Published As

Publication number Publication date
CN1819990A (zh) 2006-08-16
TWI330173B (en) 2010-09-11
MXPA06000294A (es) 2006-04-18
US7378446B2 (en) 2008-05-27
CA2531790A1 (en) 2005-01-20
JPWO2005005372A1 (ja) 2006-08-24
NZ545102A (en) 2008-11-28
MY143775A (en) 2011-07-15
TW200524847A (en) 2005-08-01
EP1661882B1 (en) 2013-10-30
RU2346933C2 (ru) 2009-02-20
EP1661882A4 (en) 2007-01-31
US20060194870A1 (en) 2006-08-31
JP4068639B2 (ja) 2008-03-26
CN1819990B (zh) 2010-04-21
EP1661882A1 (en) 2006-05-31
AU2004255633A1 (en) 2005-01-20
AU2004255633B2 (en) 2009-08-06
KR20060029182A (ko) 2006-04-04
WO2005005372A1 (ja) 2005-01-20
RU2006103803A (ru) 2006-08-10
IL172666A0 (en) 2006-04-10
UA92134C2 (ru) 2010-10-11
HK1093485A1 (zh) 2007-03-02
NO20055986L (no) 2006-02-13

Similar Documents

Publication Publication Date Title
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2006122011A3 (en) Thiazole compounds and methods of use
HUP0400206A2 (hu) Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
BR0310006A (pt) Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
BRPI0313694B8 (pt) derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção
RU2002124873A (ru) Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI9504791B8 (pt) composto de polipeptídeo e composição farmacêutica.
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
BR0314314A (pt) Derivados do éter 4-pirrolidina-fenil-benzìlico
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
BRPI0515628A (pt) composto de 2-morfolina-4-pirimidona
NO20071321L (no) Anti-inflammatoriske midler
MY143775A (en) Compound having anti-hcv action
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
CY1109546T1 (el) Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας
BRPI0407140A (pt) Droga terapêutica para vìrus
KR910700230A (ko) 신규 히드록실아민 유도체

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.